These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4382 related articles for article (PubMed ID: 29492876)

  • 21. Bile Acid-Gut Microbiota Axis in Inflammatory Bowel Disease: From Bench to Bedside.
    Yang M; Gu Y; Li L; Liu T; Song X; Sun Y; Cao X; Wang B; Jiang K; Cao H
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoration of dysbiotic human gut microbiome for homeostasis.
    Dixit K; Chaudhari D; Dhotre D; Shouche Y; Saroj S
    Life Sci; 2021 Aug; 278():119622. PubMed ID: 34015282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory Bowel Diseases and Gut Microbiota.
    Haneishi Y; Furuya Y; Hasegawa M; Picarelli A; Rossi M; Miyamoto J
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy.
    Cammarota G; Ianiro G; Cianci R; Bibbò S; Gasbarrini A; Currò D
    Pharmacol Ther; 2015 May; 149():191-212. PubMed ID: 25561343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotics, probiotics and prebiotics in IBD.
    Bernstein CN
    Nestle Nutr Inst Workshop Ser; 2014; 79():83-100. PubMed ID: 25227297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal Microbiota Transplantation in Inflammatory Bowel Disease.
    Reinisch W
    Dig Dis; 2017; 35(1-2):123-126. PubMed ID: 28147375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease.
    Li L; Liu T; Gu Y; Wang X; Xie R; Sun Y; Wang B; Cao H
    Front Immunol; 2022; 13():974305. PubMed ID: 36211363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
    Haak BW; Prescott HC; Wiersinga WJ
    Front Immunol; 2018; 9():2042. PubMed ID: 30250472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis.
    Yu LC
    J Biomed Sci; 2018 Nov; 25(1):79. PubMed ID: 30413188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut microbiota and acute graft-versus-host disease.
    Yoshioka K; Kakihana K; Doki N; Ohashi K
    Pharmacol Res; 2017 Aug; 122():90-95. PubMed ID: 28576475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fiber and Prebiotic Interventions in Pediatric Inflammatory Bowel Disease: What Role Does the Gut Microbiome Play?
    Healey GR; Celiberto LS; Lee SM; Jacobson K
    Nutrients; 2020 Oct; 12(10):. PubMed ID: 33092150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of enteric dysbacteriosis and modulation of gut microbiota in the treatment of inflammatory bowel disease.
    Niu W; Yang F; Fu Z; Dong Y; Zhang Z; Ju J
    Microb Pathog; 2022 Apr; 165():105381. PubMed ID: 34974123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease.
    Gonçalves P; Araújo JR; Di Santo JP
    Inflamm Bowel Dis; 2018 Feb; 24(3):558-572. PubMed ID: 29462379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Insights into the Role of Oral Microbiota Dysbiosis in the Pathogenesis of Inflammatory Bowel Disease.
    Qi Y; Wu HM; Yang Z; Zhou YF; Jin L; Yang MF; Wang FY
    Dig Dis Sci; 2022 Jan; 67(1):42-55. PubMed ID: 33527328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory Bowel Diseases: The Role of Gut Microbiota.
    De Musis C; Granata L; Dallio M; Miranda A; Gravina AG; Romano M
    Curr Pharm Des; 2020; 26(25):2951-2961. PubMed ID: 32310042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood.
    Eindor-Abarbanel A; Healey GR; Jacobson K
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota.
    Peterson CT; Sharma V; Elmén L; Peterson SN
    Clin Exp Immunol; 2015 Mar; 179(3):363-77. PubMed ID: 25345825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis.
    Ray A; Dittel BN
    Immunology; 2015 Nov; 146(3):359-68. PubMed ID: 26211540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intestinal immune response is regulated by gut microbe].
    Tanemoto S; Sujino T; Kanai T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(6):408-415. PubMed ID: 29367525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 220.